Bottom line
Is LMORX a good fund? The bottom line
LMORX is the Class R share class of Patient Opportunity Trust, a managed large blend mutual fund from Tortoise.
Annual fees run 1.94% — about $194 a year on every $10,000 invested, more expensive than 92% of large blend funds we track.
It returned +27.1% over one year, +6.5% a year over five years, +11.0% a year over ten (as of Dec 31, 2025, per its prospectus).
With $2.0 billion in net assets and 38 holdings, its largest position is Royalty Pharma PLC (7.0%) and the top 10 make up 54.8% of the portfolio.
What stands out
- No front-end sales load
What to watch
- Expensive for its category (1.94%)
- Concentrated: top 10 holdings are 54.8% of assets
- 12b-1 marketing fee of 0.5% a year
Updated Nov 19, 2026
What LMORX invests in
The Patient Opportunity Trust (the Fund) seeks long term growth of capital.
"The Fund normally makes investments that, in the portfolio managers opinion, offer the opportunity for long-term growth of capital. The portfolio managers exercise a flexible strategy in the selection of investments, not limited by investment style or asset class. The investment strategy typically involves identifying instances where the Advisor believes the capital markets have mispriced investment opportunities and exploiting price discrepancies and inefficiencies in the market. The Fund may invest without limit in the common stock of U.S. and foreign issuers (including securities denominated in foreign currencies) of all sizes and in other U.S. and foreign securities, including emerging markets, and including: securities convertible into common stock; securities issued through private placements; preferred securities; warrants and rights; securities issued by investment companies…
From the fund's prospectus (filed Apr 30, 2026).
LMORX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| LMORX | +27.1% | +6.5% | +11.0% |
| Large Blend median | +13.8% | +9.7% | +10.9% |
Source: Fund prospectus, as of Dec 31, 2025
What LMORX costs
On a $10,000 investment, LMORX's 1.94% expense ratio costs about $194 a year. The prospectus estimates $2,264 in total costs over 10 years (assuming 5% annual returns). The median large blend fund charges 0.83%.
LMORX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Royalty Pharma PLC RPRX | 6.98% |
| 2 | Citigroup Inc C | 6.97% |
| 3 | Alphabet Inc GOOGL | 6.67% |
| 4 | UnitedHealth Group Inc UNH | 6.21% |
| 5 | Amazon.com Inc AMZN | 5.64% |
| 6 | NVIDIA Corp NVDA | 4.98% |
| 7 | CVS Health Corp CVS | 4.51% |
| 8 | QXO Inc QXO | 4.48% |
| 9 | Norwegian Cruise Line Holdings NCLH | 4.21% |
| 10 | Precigen Warrant Restricted | 4.19% |
Source: SEC Form N-PORT, period ended Jun 30, 2026
The top 10 make up 54.8% of the fund. See all top 25 holdings and asset mix →